• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025

    Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025

    Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025

    Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million

    Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com.

    "It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine," said Andrew Dudum, co-founder and CEO. "We believe we're entering an exciting period of growth where we'll enter new, high-impact specialties that bring millions of people in need of care into the market. We expect this broadening offering will transform our platform from a place where customers come to solve a single issue, to one where customers can proactively manage their overall health."

    Yemi Okupe, CFO, stated, "We're seeing consistent growth across our business as we continue to democratize access to precision care. In the second quarter, revenue grew 73% and Adjusted EBITDA more than doubled relative to the prior year; both were driven by robust growth in Subscribers utilizing personalized treatment plans. As we move into the second half of 2025, our focus is on investing in capabilities that will deepen the value customers can access on our platform. This includes plans to strengthen the personalization infrastructure in our pharmacies, to expand lab testing capabilities to further tailor care, and to grow our international presence in key markets."

    Key Business Metrics

    (In Thousands, Except for Monthly Online Revenue per Average Subscriber, Unaudited)

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Subscribers (end of period)

     

     

    2,439

     

     

    1,864

     

    31

    %

     

     

    2,439

     

     

    1,864

     

    31

    %

    Monthly Online Revenue per Average Subscriber

     

    $

    74

     

    $

    57

     

    30

    %

     

    $

    79

     

    $

    56

     

    41

    %

     

    Revenue

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2025

     

    2024

     

    % Change

     

    2025

     

    2024

     

    % Change

    Online Revenue

     

    $

    536,880

     

    $

    306,843

     

    75

    %

     

    $

    1,113,241

     

    $

    574,604

     

    94

    %

    Wholesale Revenue

     

     

    7,953

     

     

    8,805

     

    (10

    )%

     

     

    17,602

     

     

    19,215

     

    (8

    )%

    Total revenue

     

    $

    544,833

     

    $

    315,648

     

    73

    %

     

    $

    1,130,843

     

    $

    593,819

     

    90

    %

    Second Quarter 2025 Financial Highlights

    • Revenue was $544.8 million for the second quarter of 2025 compared to $315.6 million for the second quarter of 2024, an increase of 73% year-over-year.
    • Gross margin was 76% for the second quarter of 2025 compared to 81% for the second quarter of 2024.
    • Net income was $42.5 million for the second quarter of 2025 compared to $13.3 million for the second quarter of 2024.
    • Adjusted EBITDA was $82.2 million for the second quarter of 2025 compared to $39.3 million for the second quarter of 2024.
    • Net cash used in operating activities was $(19.1) million for the second quarter of 2025 compared to net cash provided by operating activities of $53.6 million for the second quarter of 2024.
    • Free Cash Flow was $(69.4) million for the second quarter of 2025 compared to $47.6 million for the second quarter of 2024.

    Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net income and net cash (used in) provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States ("U.S. GAAP"), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading "Non-GAAP Financial Measures".

    Financial Outlook

    Hims & Hers is providing the following guidance:

    For the third quarter 2025, we expect:

    • Revenue of $570 million to $590 million.
    • Adjusted EBITDA of $60 million to $70 million, reflecting an Adjusted EBITDA margin of 11% to 12%.

    For the full year 2025, we expect:

    • Revenue of $2.3 billion to $2.4 billion.
    • Adjusted EBITDA of $295 million to $335 million, reflecting an Adjusted EBITDA margin of 13% to 14%.

    The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

    We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

    Conference Call

    Hims & Hers will host a conference call to review the second quarter 2025 results on August 4, 2025, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

    About Hims & Hers Health, Inc.

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

    We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

    For more information, please visit investors.hims.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believe," "estimate," "anticipate," "expect," "assume," "imply," "intend," "plan," "may," "will," "potential," "project," "predict," "continue," "could," "confident," "confidence," or "should," or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the timing and anticipated effect of any pending or recently completed acquisitions, the success of our business model, our market opportunity, our ability to scale our business and expand internationally, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, including through the use of data analytics and artificial intelligence, our ability to reinvest into the customer experience, our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions in relation to any such legal and regulatory requirements. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

    The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the "Commission").

    Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.

    By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

    Key Business Metrics

    "Online Revenue" represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

    "Wholesale Revenue" represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms.

    "Subscribers" are customers who have one or more "Subscriptions" pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services.

    "Monthly Online Revenue per Average Subscriber" is defined as Online Revenue divided by "Average Subscribers", which amount is then further divided by the number of months in a period. "Average Subscribers" are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

     

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

    June 30, 2025

     

    December 31, 2024

     

     

     

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    1,124,582

     

     

    $

    220,584

     

    Short-term investments

     

    20,033

     

     

     

    79,667

     

    Inventory

     

    141,800

     

     

     

    64,427

     

    Prepaid expenses and other current assets

     

    69,151

     

     

     

    31,153

     

    Total current assets

     

    1,355,566

     

     

     

    395,831

     

    Restricted cash

     

    368

     

     

     

    856

     

    Goodwill

     

    117,753

     

     

     

    112,728

     

    Property, equipment, and software, net

     

    205,480

     

     

     

    82,083

     

    Intangible assets, net

     

    40,657

     

     

     

    43,410

     

    Operating lease right-of-use assets

     

    71,661

     

     

     

    10,881

     

    Deferred tax assets, net

     

    84,229

     

     

     

    61,603

     

    Other long-term assets

     

    1,868

     

     

     

    147

     

    Total assets

    $

    1,877,582

     

     

    $

    707,539

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    105,009

     

     

    $

    91,180

     

    Accrued liabilities

     

    65,671

     

     

     

    53,013

     

    Deferred revenue

     

    98,417

     

     

     

    75,285

     

    Operating lease liabilities

     

    3,135

     

     

     

    1,889

     

    Total current liabilities

     

    272,232

     

     

     

    221,367

     

    Convertible senior notes, net

     

    969,467

     

     

     

    —

     

    Operating lease liabilities

     

    71,786

     

     

     

    9,456

     

    Other long-term liabilities

     

    1,401

     

     

     

    —

     

    Total liabilities

     

    1,314,886

     

     

     

    230,823

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 217,381,434 and 212,459,586 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of June 30, 2025 and December 31, 2024

     

    23

     

     

     

    22

     

    Additional paid-in capital

     

    711,998

     

     

     

    719,155

     

    Accumulated other comprehensive income (loss)

     

    822

     

     

     

    (324

    )

    Accumulated deficit

     

    (150,147

    )

     

     

    (242,137

    )

    Total stockholders' equity

     

    562,696

     

     

     

    476,716

     

    Total liabilities and stockholders' equity

    $

    1,877,582

     

     

    $

    707,539

     

     

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

    (In Thousands, Except Share and Per Share Data, Unaudited)

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Revenue

     

    $

    544,833

     

     

    $

    315,648

     

     

    $

    1,130,843

     

     

    $

    593,819

     

    Cost of revenue

     

     

    128,637

     

     

     

    59,035

     

     

     

    283,958

     

     

     

    108,111

     

    Gross profit

     

     

    416,196

     

     

     

    256,613

     

     

     

    846,885

     

     

     

    485,708

     

    Gross margin %

     

     

    76

    %

     

     

    81

    %

     

     

    75

    %

     

     

    82

    %

    Operating expenses:(1)

     

     

     

     

     

     

     

     

    Marketing

     

     

    217,862

     

     

     

    144,922

     

     

     

    449,097

     

     

     

    275,475

     

    Operations and support

     

     

    66,490

     

     

     

    41,453

     

     

     

    129,523

     

     

     

    80,200

     

    Technology and development

     

     

    37,848

     

     

     

    18,654

     

     

     

    67,762

     

     

     

    33,978

     

    General and administrative

     

     

    67,273

     

     

     

    40,554

     

     

     

    115,883

     

     

     

    75,122

     

    Total operating expenses

     

     

    389,473

     

     

     

    245,583

     

     

     

    762,265

     

     

     

    464,775

     

    Income from operations

     

     

    26,723

     

     

     

    11,030

     

     

     

    84,620

     

     

     

    20,933

     

    Other income and expense, net

     

     

    6,130

     

     

     

    2,394

     

     

     

    8,728

     

     

     

    4,894

     

    Income before income taxes

     

     

    32,853

     

     

     

    13,424

     

     

     

    93,348

     

     

     

    25,827

     

    Benefit (provision) for income taxes

     

     

    9,652

     

     

     

    (127

    )

     

     

    (1,358

    )

     

     

    (1,402

    )

    Net income

     

     

    42,505

     

     

     

    13,297

     

     

     

    91,990

     

     

     

    24,425

     

    Other comprehensive income (loss)

     

     

    986

     

     

     

    (6

    )

     

     

    1,146

     

     

     

    (44

    )

    Total comprehensive income

     

    $

    43,491

     

     

    $

    13,291

     

     

    $

    93,136

     

     

    $

    24,381

     

     

     

     

     

     

     

     

     

     

    Net income per share attributable to common stockholders:

     

     

     

     

     

     

     

     

    Basic

     

    $

    0.19

     

     

    $

    0.06

     

     

    $

    0.41

     

     

    $

    0.11

     

    Diluted

     

    $

    0.17

     

     

    $

    0.06

     

     

    $

    0.37

     

     

    $

    0.11

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

     

    Basic

     

     

    224,373,375

     

     

     

    214,618,037

     

     

     

    223,187,936

     

     

     

    214,035,065

     

    Diluted

     

     

    256,779,292

     

     

     

    234,791,985

     

     

     

    251,894,929

     

     

     

    232,583,676

     

    ______________

    (1) Includes stock-based compensation expense as follows (in thousands):

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2025

     

    2024

     

    2025

     

    2024

    Marketing

     

    $

    3,435

     

    $

    2,393

     

    $

    6,209

     

    $

    4,297

    Operations and support

     

     

    4,579

     

     

    2,702

     

     

    7,585

     

     

    4,857

    Technology and development

     

     

    5,247

     

     

    3,195

     

     

    9,292

     

     

    5,400

    General and administrative

     

     

    22,465

     

     

    15,752

     

     

    37,498

     

     

    28,520

    Total stock-based compensation expense

     

    $

    35,726

     

    $

    24,042

     

    $

    60,584

     

    $

    43,074

     

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In Thousands, Unaudited)

     

     

    Six Months Ended

    June 30,

     

     

    2025

     

     

     

    2024

     

    Operating activities

     

     

     

    Net income

    $

    91,990

     

     

    $

    24,425

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    18,741

     

     

     

    6,644

     

    Stock-based compensation

     

    60,584

     

     

     

    43,074

     

    Net accretion on securities

     

    (1,060

    )

     

     

    (2,281

    )

    Benefit for deferred taxes

     

    (10,346

    )

     

     

    —

     

    Impairment of long-lived assets

     

    —

     

     

     

    114

     

    Amortization of debt discount and issuance costs

     

    1,047

     

     

     

    —

     

    Non-cash operating lease cost

     

    4,594

     

     

     

    1,221

     

    Non-cash acquisition-related costs

     

    2,985

     

     

     

    —

     

    Non-cash other

     

    (1,315

    )

     

     

    412

     

    Changes in operating assets and liabilities:

     

     

     

    Inventory

     

    (77,373

    )

     

     

    (18,124

    )

    Prepaid expenses and other current assets

     

    (38,081

    )

     

     

    (1,430

    )

    Other long-term assets

     

    (10

    )

     

     

    (47

    )

    Accounts payable

     

    5,146

     

     

     

    16,156

     

    Accrued liabilities

     

    11,737

     

     

     

    (24

    )

    Deferred revenue

     

    23,132

     

     

     

    13,257

     

    Operating lease liabilities

     

    (1,798

    )

     

     

    (1,140

    )

    Earn-out payable

     

    —

     

     

     

    (2,825

    )

    Net cash provided by operating activities

     

    89,973

     

     

     

    79,432

     

    Investing activities

     

     

     

    Purchases of investments

     

    —

     

     

     

    (97,539

    )

    Maturities of investments

     

    60,569

     

     

     

    126,095

     

    Investment in website development and internal-use software

     

    (7,961

    )

     

     

    (6,191

    )

    Purchases of property, equipment, and intangible assets

     

    (101,392

    )

     

     

    (13,793

    )

    Acquisition of business, net of cash acquired

     

    (5,100

    )

     

     

    —

     

    Net cash (used in) provided by investing activities

     

    (53,884

    )

     

     

    8,572

     

    Financing activities

     

     

     

    Proceeds from issuance of convertible senior notes, net of debt discount

     

    970,000

     

     

     

    —

     

    Purchases of capped calls related to convertible senior notes

     

    (47,800

    )

     

     

    —

     

    Proceeds from exercise of vested stock options

     

    6,497

     

     

     

    16,472

     

    Payments for taxes related to net share settlement of equity awards

     

    (62,475

    )

     

     

    (22,281

    )

    Proceeds from employee stock purchase plan

     

    2,970

     

     

     

    1,622

     

    Payments for debt issuance costs

     

    (3,041

    )

     

     

    —

     

    Repurchases of common stock

     

    —

     

     

     

    (47,996

    )

    Payments for acquisition-related earn-out consideration

     

    —

     

     

     

    (3,190

    )

    Net cash provided by (used in) financing activities

     

    866,151

     

     

     

    (55,373

    )

    Foreign currency effect on cash and cash equivalents

     

    1,270

     

     

     

    1

     

    Increase in cash, cash equivalents, and restricted cash

     

    903,510

     

     

     

    32,632

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    221,440

     

     

     

    97,519

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    1,124,950

     

     

    $

    130,151

     

    Reconciliation of cash, cash equivalents, and restricted cash

     

     

     

    Cash and cash equivalents

    $

    1,124,582

     

     

    $

    129,295

     

    Restricted cash

     

    368

     

     

     

    856

     

    Total cash, cash equivalents, and restricted cash

    $

    1,124,950

     

     

    $

    130,151

     

    Supplemental disclosures of cash flow information

     

     

     

    Cash paid for taxes

    $

    23,047

     

     

    $

    3,468

     

    Non-cash investing and financing activities

     

     

     

    Purchases of property and equipment included in accounts payable and accrued liabilities

    $

    16,954

     

     

    $

    1,256

     

    Deferred debt issuance costs included in accounts payable and accrued liabilities

     

    249

     

     

     

    —

     

    Right-of-use asset obtained in exchange for lease liability

     

    63,434

     

     

     

    2,174

     

    Issuance of common stock in connection with asset acquisition

     

    12,760

     

     

     

    —

     

    Common stock to be issued for asset acquisition indemnification holdback

     

    6,380

     

     

     

    —

     

    Issuance of common stock for acquisition-related earn-out consideration

     

    —

     

     

     

    1,396

     

     

    Non-GAAP Financial Measures

    In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

    However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

    Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net income before stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), payroll tax expense related to stock-based compensation, impairment of long-lived assets, interest income and expense, net, and income taxes. "Adjusted EBITDA margin" is defined as Adjusted EBITDA divided by revenue.

    In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation.

    Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income and other U.S. GAAP results.

     

    Net Income to Adjusted EBITDA Reconciliation

    (In Thousands, Unaudited)

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

     

     

     

     

     

     

     

     

    Revenue

    $

    544,833

     

     

    $

    315,648

     

     

    $

    1,130,843

     

     

    $

    593,819

     

     

     

     

     

     

     

     

     

    Net income

     

    42,505

     

     

     

    13,297

     

     

     

    91,990

     

     

     

    24,425

     

    Stock-based compensation

     

    35,726

     

     

     

    24,042

     

     

     

    60,584

     

     

     

    43,074

     

    Depreciation and amortization

     

    10,465

     

     

     

    3,643

     

     

     

    18,741

     

     

     

    6,644

     

    Acquisition and transaction-related costs

     

    6,231

     

     

     

    590

     

     

     

    6,255

     

     

     

    966

     

    Payroll tax expense related to stock-based compensation

     

    3,078

     

     

     

    —

     

     

     

    3,078

     

     

     

    —

     

    Impairment of long-lived assets

     

    —

     

     

     

    39

     

     

     

    —

     

     

     

    114

     

    Interest income and expense, net

     

    (6,117

    )

     

     

    (2,431

    )

     

     

    (8,713

    )

     

     

    (4,971

    )

    (Benefit) provision for income taxes

     

    (9,652

    )

     

     

    127

     

     

     

    1,358

     

     

     

    1,402

     

    Adjusted EBITDA

    $

    82,236

     

     

    $

    39,307

     

     

    $

    173,293

     

     

    $

    71,654

     

     

     

     

     

     

     

     

     

    Net income as a % of revenue

     

    8

    %

     

     

    4

    %

     

     

    8

    %

     

     

    4

    %

    Adjusted EBITDA margin

     

    15

    %

     

     

    12

    %

     

     

    15

    %

     

     

    12

    %

     

    Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. "Free Cash Flow" is defined as net cash (used in) provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

    Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash (used in) provided by operating activities and other U.S. GAAP results.

    Net Cash (Used In) Provided By Operating Activities to Free Cash Flow Reconciliation

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended

    June 30,

     

    Six Months Ended

    June 30,

     

     

     

    2025

     

     

     

    2024

     

     

     

    2025

     

     

     

    2024

     

    Net cash (used in) provided by operating activities

     

    $

    (19,117

    )

     

    $

    53,594

     

     

    $

    89,973

     

     

    $

    79,432

     

    Less: purchases of property, equipment, and intangible assets in investing activities

     

     

    (46,065

    )

     

     

    (3,212

    )

     

     

    (101,392

    )

     

     

    (13,793

    )

    Less: investment in website development and internal-use software in investing activities

     

     

    (4,250

    )

     

     

    (2,814

    )

     

     

    (7,961

    )

     

     

    (6,191

    )

    Free Cash Flow

     

    $

    (69,432

    )

     

    $

    47,568

     

     

    $

    (19,380

    )

     

    $

    59,448

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250804179846/en/

    Investor Relations

    Bill Newby

    [email protected]

    Media Relations

    Abby Reisinger-Moley

    [email protected]

    Get the next $HIMS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    More analyst ratings

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 11,581 shares at a strike of $5.01 and sold $556,420 worth of shares (11,581 units at $48.05), increasing direct ownership by 116% to 116,806 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/15/25 4:18:27 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Legal Officer Boughton Soleil sold $132,818 worth of shares (2,572 units at $51.64), decreasing direct ownership by 2% to 153,021 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/12/25 4:33:50 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Dudum Andrew sold $33,384,120 worth of shares (660,000 units at $50.58) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/11/25 5:07:29 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first approach to weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success. In a first-of-its-kind U.S. analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects. Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success.1 This press

    7/29/25 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme

    7/14/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form SCHEDULE 13G filed by Hims & Hers Health Inc.

    SCHEDULE 13G - Hims & Hers Health, Inc. (0001773751) (Subject)

    8/13/25 12:56:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Hims & Hers Health Inc.

    10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

    8/4/25 4:18:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    8/4/25 4:13:03 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health downgraded by Needham

    Needham downgraded Hims & Hers Health from Buy to Hold

    6/23/25 11:43:05 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously

    6/4/25 7:59:55 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health downgraded by TD Cowen with a new price target

    TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

    4/29/25 8:05:51 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

    Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

    5/5/25 9:01:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme

    7/14/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

    Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

    5/5/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care